-
[show abstract]
[hide abstract]
ABSTRACT: Genistein (GEN) is a molecule of great interest as a potent chemopreventive agent against atherosclerosis and cancer. However, the bioavailability of GEN is very low in vivo. Our previous study showed that a GEN derivative, 7-difluoromethyl-5,4'-dimethoxygenistein (dFMGEN) has a better bioavailability than GEN in vivo. In this study, we further evaluated the efficacy of dFMGEN as a candidate for cancer therapy. We demonstrated that dFMGEN treatment decreased the viability of A549 cells in a concentration- and time-dependent manner and induced cell-cycle arrest at the G(1) phase. G(1) phase arrest was correlated with a significant reduction of Cdk4 and cyclin D1 protein level. Further studies showed that cyclin-dependent kinase (Cdk)4 and cyclin D1 protein-level decrease was caused by Cdk inhibitors p15, p21, and p27 level increase, and decreased protein level directly suppressed Rb protein phosphorylation and E2F-1 expression, then cell-cycle progression was arrested. Finally, we also found that dFMGEN has a dosage effect in suppressing tumor growth in vivo, and that dFMGEN was well tolerated by animals. In summary, our results suggest that dFMGEN has therapeutic potential for the treatment of human lung cancer.
Drug and Chemical Toxicology 08/2012; · 1.08 Impact Factor
-
Wei Hu, Chengkun Wang,
Jingdan Liang,
Tianlong Zhang,
Zhongpei Hu,
Zhijun Wang,
Wenxian Lan,
Fang Li,
Houming Wu,
Jianping Ding,
Geng Wu,
Zixin Deng,
Chunyang Cao
Cell Research 04/2012; 22(7):1203-6. · 8.19 Impact Factor
-
Chengkun Wang,
Jie Shen,
Zhongzheng Yang,
Ping Chen,
Bin Zhao,
Wei Hu,
Wenxian Lan,
Xiaotian Tong,
Houming Wu,
Guohong Li,
Chunyang Cao
Cell Research 08/2011; 21(9):1379-82. · 8.19 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Angiogenesis is an innovative target in the therapy of cancer and other diseases, but the effects of anti-angiogenic drugs have been rather modest in clinical trials. We have developed a small peptide, recombinant vascular basement membrane derived multifunctional peptide (rVBMDMP), which significantly inhibits endothelial cells in vitro. Here we test the mechanisms of rVBMDMP in angiogenesis balance in assays of tubule formation, colony formation, and apoptosis in HUVE-12 endothelial cells. We also analyzed the differential expression of phosphorylation proteins and related genes in a protein phosphorylation chip and extracellular matrix adhesion molecule cDNA microarray, and validated changes with Western blot or real-time quantitative PCR, respectively. rVBMDMP dose-dependently inhibited colony formation, induced apoptosis, and inhibited in vitro tubule formation. rVBMDMP increased the phosphorylation of 88 signal proteins, including caspase-3, death receptor 3, 4, and 5, and integrin αV, β1, and β3, and down-regulated 41 signal proteins, including EGFR, pEGFR, VEGFR-1, and survivin versus control. rVBMDMP upregulated 14 genes, including collagen 4, 7, and 27, and down-regulated 21 genes, including integrin αVβ3, MMP10, and MMP12. Our study suggests that rVBMDMP inhibits angiogenesis and may be a viable drug candidate in anti-angiogenesis and anticancer therapies.
Journal of Cellular Biochemistry 10/2010; 111(2):453-60. · 2.87 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Breast cancer resistance protein (BCRP) has been shown to confer multidrug resistance, but the mechanisms of its regulation are poorly understood. Here, we investigate the effects of wild-type and mutant p53, and nuclear factor kappa-B (NF-kappaB) (p50) on BCRP promoter activity in MCF-7 cells. Our results demonstrated that wild-type p53 markedly suppressed BCRP activity and enhanced the chemosensitivity of cells to mitoxantrone, whereas mutant p53 had little inhibitory effect. After inhibition of NF-kappaB, similar results were obtained. Following knockdown of endogenous p53, BCRP and p50 expressions were increased, and the chemosensitivity of the cells to mitoxantrone was decreased. We conclude that wild-type p53 acts as a negative regulator of BCRP gene transcription.
FEBS letters 08/2010; 584(15):3392-7. · 3.54 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Street dust was collected from five roads with different traffic volumes in the metropolitan area of Beijing and separated into five size fractions. Concentrations of polycyclic aromatic hydrocarbons (PAHs) adsorbed on street dust in different size ranges and their correlation with specific surface area and total organic carbon (TOC) were investigated. Results show that the concentration of 16-PAHs of sieved samples ranges from 0.27 to 1.30 mg/kg for all the sampling sites. Particles smaller than 40 mum in diameter have the highest 16-PAHs concentration among all of the size ranges for street dust from the four sampling sites with vehicles running on. PAHs with three or four rings account for 68% of the overall 16-PAHs on average. Remarkable positive correlation exists between 16-PAHs concentration and specific surface area with R(2) values from 0.7 to 0.96 for the four sampling sites with vehicles running on. The relationship between the concentration of 16-PAHs and TOC is less clear.
Environmental Monitoring and Assessment 10/2009; 169(1-4):661-70. · 1.40 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Chemotherapy is not only important but also necessary for the patient of breast cancer. Breast cancer resistance protein (BCRP), an atypical drug efflux pump, mediates multidrug resistance in breast cancer. The aim of this study is to search new substrate of BCRP. The result will guide the drug selection of chemotherapy in BCRP-positive breast cancer.
PA317/Tet-on/TRE-BCRP cell induced with doxycycline was used to screen the possible substrates of BCRP by MTT assay. The suspicious substrate [5-fluorouracil (5-Fu)] was further confirmed in PA317 and breast cancer cell MCF-7 by HLCP, apoptosis assay (staining and FACS) and RNAi technique.
Mitoxantrone, 5-Fu, adriamycin, Methotrexate, Pirarubicin, and Etoposide were identified as substrates of BCRP. However, Paclitaxel, Vincristine, Vindesine, Mitomycin C, and cisplatin were not mediated by BCRP. 5-Fu was identified as substrate of BCRP for the first time. The further study showed that the intracellular retention dose of 5-Fu and the 5-Fu induced cellular apoptosis all decreased when BCRP highly expressed. Furthermore, 5-Fu accumulation and 5-Fu induced DNA damage increased when BCRP was silenced by RNAi in breast cancer cells.
5-Fluorouracil may be a specific substrate which can be bound by BCRP. BCRP can predict the sensitivity of breast cancer to 5-Fu. And BCRP-targeted therapy will reverse the resistance of breast cancer to 5-Fu.
Cancer Chemotherapy and Pharmacology 10/2008; 63(6):1103-10. · 2.83 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Latent membrane protein 1 (LMP1) of Epstein-Barr virus has been identified to be crucial in inducing cell transformation. However, the mechanism of LMP1-mediated epithelial cell transformation remains unclear. In this study, nasopharyngeal epithelial cells NP69 were infected with retrovirus with gene encoding wild type LMP1 or mutational LMP1 defective in binding to tumor necrosis factor receptor-associated death domain (TRADD). The NP69-LMP1(TRADD) lost some malignant phenotypes compared with the NP69-LMP1(WT). We performed proteomic approach to gain the differential protein expression profile associated with LMP1-mediated epithelial cell transformation. Furthermore, the differential expressional levels of partial identified proteins were confirmed by Western blot and real-time RT-PCR. Some were known to be related to the development of LMP1-induced transformation, and some were new LMP1-associated proteins. These data are valuable for further study of the mechanism of LMP1 in human nasopharyngeal carcinoma and provide some new clues for investigating other LMP1-associated tumors.
Molecular and Cellular Biochemistry 08/2008; 314(1-2):73-83. · 2.06 Impact Factor
